Paris-based biotech startup Generare just closed a €20 million Series A round to supercharge its hunt for new drug compounds hiding in microbial DNA. With billions of years of untapped chemistry sitting in soil bacteria and fungi, this fresh funding could reshape how the world discovers the next generation of medicines.
What the New Funding Means for Generare
2 The €20 million Series A financing round, announced on April 2, 2026, will support the expansion of Generare’s proprietary dataset of novel small molecules and scale its discovery capacity tenfold by 2027 to meet increasing demand from pharmaceutical and agrochemical companies. 1 The round was co-led by Alven and Daphni, with all existing investors including Galion.exe, Teampact Ventures, and VIVES Partners re-upping. 1 The round follows a €5 million seed in 2024.
In total, Generare has now raised €25 million since its founding in 2023.
1 The Series A will fund a tenfold scale-up of the molecule library by 2027, from roughly 200 to 2,000+ compounds, with a longer-term target of 10,000 over time. The team of 25, computational biologists, chemists, synthetic biologists, technicians, and engineers drawn from France, the UK, the US, Germany, and Australia, will be nearly doubled.
Here is a quick look at the key numbers:
| Metric | Current | 2027 Target | Long-Term Goal |
|---|---|---|---|
| Molecules Characterized | 200+ | 2,000+ | 10,000+ |
| Team Size | 25 | ~50 | Growing |
| Total Funding Raised | €25M | — | — |
Generare biotech microbial genome drug discovery platform funding
Why 97% of Microbial Chemistry Remains Untapped
The science behind Generare’s approach is rooted in a simple but powerful idea.
1 Microorganisms, bacteria, fungi, and other microbes encode molecular chemistry in their genes: biological recipes for small molecules shaped by three billion years of evolutionary pressure. 1 Generare estimates that approximately 97% of the molecular chemistry encoded in microbial genomes remains uncharacterized. 3 More than 500 FDA-approved drugs originate from microbial chemistry. Penicillin, rapamycin, vancomycin are all evolution-derived. Yet the pharmaceutical industry moved away from natural product discovery decades ago.
Not because the chemistry ran out. Because the tools to read it did not exist.
8 Six out of every 1,000 molecules discovered from microbial origins are typically granted FDA approval as drugs, a success rate more than 100 times higher than molecules derived from plants or combinatorial chemistry. That stat alone explains why investors are paying close attention.
How Generare’s Discovery Platform Works
1 The company’s platform uses high-throughput cloning and sequencing technology, validated through ERC-funded academic research and peer-reviewed publications, to screen tens of thousands of microbial genomes, identify the gene sequences most likely to produce bioactive molecules, express them, and characterize the resulting compounds for structure, biological activity, and drug potential.
Think of it like reading genetic cookbooks buried in soil bacteria. Each cookbook holds a recipe for a unique molecule. Most of these recipes have never been opened.
9 Instead of slow, expensive techniques that target specific gene clusters, Generare employs a method called “shotgun cloning.” This process involves breaking down the genomes of thousands of soil bacteria into millions of random fragments. Each fragment is then cloned and analyzed in parallel to identify bioactive molecules, such as those with antibiotic or anticancer properties.
Every new molecule discovered feeds back into the platform, improving the next round of predictions. 7As Generare collects more data, it enhances its understanding of which clusters are most productive. This creates a virtuous cycle of discovery and improves the likelihood of finding “first-in-class” molecules with high potential.
The Founders and the Team Behind the Mission
1 The company was founded by CEO Guillaume Vandenesch and CSO Dr. Vincent Libis, who brings a decade of synthetic biology research, ERC grant funding, and prior co-founding experience at Abolis Biotechnologies. 7 Vandenesch scaled Hello Tomorrow, a global non-profit accelerating deep tech startups, and successfully exited Possible Future to CapGemini in 2022. 7 Dr. Vincent Libis co-founded Abolis Biotechnologies, served as a postdoctoral researcher at Rockefeller University, and currently holds a Chair on Antibiotic Resistance at INSERM.
The advisory board adds serious pharma credibility. 1Advisors include Dr. Frank Petersen, former Executive Director of Novartis’s Natural Products Chemistry Department, and Professor Nadine Ziemert, described as one of Europe’s foremost experts on microbial biosynthetic gene clusters.
7 Co-founder Vincent Libis was awarded the prestigious ERC Starting Grant, recognizing projects of groundbreaking potential. Generare was also named a 2024 i-Lab Prize winner for the most promising deeptech projects in France.
Why This Matters for the Future of Drug Discovery
The timing of this raise is no accident. Drug discovery in 2026 is at a crossroads.
27 Over 173 AI-discovered drugs are in clinical trials. With 15 to 20 entering pivotal Phase III in 2026, the industry faces its first real test. But there is a growing problem that even the most powerful AI models cannot solve on their own. 32 The limitation is rarely the models themselves; rather, it is the data environment where information lives across a dozen systems and key metadata is often missing. Poor data quality and availability are cited as the number one reason AI pilots fail, mentioned by 55 percent of organizations.
This is exactly the gap Generare is filling. As CEO Guillaume Vandenesch put it: 2“The bottleneck is not algorithms, it is the absence of genuinely novel, high-quality molecular data.”
1 The strategic argument is a data one: AI drug discovery models trained on the same recycled chemistry will keep converging on the same outcomes. Feed them genuinely novel structures with corresponding biological activity and the potential for differentiated outputs multiplies.
“Nature has been the number one source of innovative modes of action for drugs, and we’ve only scratched the surface of its potential.” Dr. Vincent Libis, CSO and Co-Founder, Generare
19 The greatest growth in biotech investing is expected to occur in areas where biotechnology intersects with digital tools between 2026 and 2027. Investors are focusing on synthetic biology, AI platforms for drug development, and personalized medicine. Generare sits squarely at that intersection. 1 The company claims to have characterized more than 200 previously unknown small molecules, with a hit rate it says matches the most successful drug discovery programs in history, and asserts that in 2025 alone it characterised five times more novel molecules than every other player in the field combined. 1 These are company-disclosed figures, not independently audited. 9 Generare operates in the biotech and pharmaceutical sectors, with potential applications in cosmetics and agriculture. The applications beyond medicine could open even bigger markets over time, from replacing traditional pesticides with natural molecules to creating novel ingredients for skincare.
In a world where antibiotic resistance is rising, cancer treatments need fresh starting points, and AI models are starving for original data, a startup that can pull brand new molecules from nature’s oldest chemistry lab feels like exactly what the industry needs. The question now is whether Generare can deliver on its ambitious scale-up targets fast enough to meet the growing hunger for novel molecular data. If you have thoughts on this story or the future of natural product drug discovery, drop a comment below.
